Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.66 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.60 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5456422 | 1.00 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| Bromide SCHEMBL5465940 | 1.00 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| SCHEMBL14363119 | 0.99 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL5470813 | 0.99 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL14363120 | 0.99 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL6104910 | 0.90 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL1486629 | 0.88 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL1486707 | 0.87 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL3863583 | 0.87 | TLR7 (0.57) | TLR7TLR8NUDT1 | |
| SCHEMBL3861898 | 0.87 | TLR7 (0.57) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | IL2, IL4, IRF3 | TLR7 55/4885TLR8 93/4885NUDT1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.